Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Charpeaud

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
Nordic Journal of Psychiatry|June 26, 2013
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?Ludovic Samalin, Aurore Nourry, Thomas Charpeaud, et al.
The Journal of Nervous and Mental Disease|July 3, 2013
Clinicians' attitudes toward the use of long-acting injectable antipsychoticsLudovic Samalin, Thomas Charpeaud, Olivier Blanc, et al.
Therapie|September 20, 2011
[Disulfiram and addiction: reminders and new perspectives of use]Thomas Charpeaud, Julie Geneste, Jeannot Schmidt, et al.
Drug Discovery Today|March 5, 2018
The development of glutamate-based antidepressants is taking longer than expectedRicardo Garay, Carlos A Zarate, Icilio Cavero, et al.
Expert Opinion on Pharmacotherapy|July 30, 2019
Pharmacotherapeutic approaches to treating depression during the perimenopauseRicardo P Garay, Thomas Charpeaud, Susan Logan, et al.
Expert Review of Neurotherapeutics|January 17, 2017
Investigational drugs in recent clinical trials for treatment-resistant depressionRicardo P Garay, Carlos A Zarate, Thomas Charpeaud, et al.
L'Encephale|February 18, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
Journal of Clinical Medicine|February 15, 2022
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Promising Treatment for Craving in Stimulant Drugs and Behavioral Addiction: A Meta-AnalysisAurélia Gay, Julien Cabe, Ingrid De Chazeron, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
L'Encephale|February 12, 2013
[Mixed states]Pierre-Michel Llorca, Thomas Charpeaud, Ludovic Samalin
Therapeutic Advances in Chronic Disease|January 24, 2013
Asenapine in bipolar I disorder: evidence and place in patient managementLudovic Samalin, Thomas Charpeaud, Pierre-Michel Llorca
Nordic Journal of Psychiatry|June 26, 2013
What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?Ludovic Samalin, Aurore Nourry, Thomas Charpeaud, et al.
The Journal of Nervous and Mental Disease|July 3, 2013
Clinicians' attitudes toward the use of long-acting injectable antipsychoticsLudovic Samalin, Thomas Charpeaud, Olivier Blanc, et al.
Therapie|September 20, 2011
[Disulfiram and addiction: reminders and new perspectives of use]Thomas Charpeaud, Julie Geneste, Jeannot Schmidt, et al.
Drug Discovery Today|March 5, 2018
The development of glutamate-based antidepressants is taking longer than expectedRicardo Garay, Carlos A Zarate, Icilio Cavero, et al.
Expert Opinion on Pharmacotherapy|July 30, 2019
Pharmacotherapeutic approaches to treating depression during the perimenopauseRicardo P Garay, Thomas Charpeaud, Susan Logan, et al.
Expert Review of Neurotherapeutics|January 17, 2017
Investigational drugs in recent clinical trials for treatment-resistant depressionRicardo P Garay, Carlos A Zarate, Thomas Charpeaud, et al.
L'Encephale|February 18, 2024
French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024Antoine Yrondi, Hervé Javelot, Bénédicte Nobile, et al.
Journal of Clinical Medicine|February 15, 2022
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Promising Treatment for Craving in Stimulant Drugs and Behavioral Addiction: A Meta-AnalysisAurélia Gay, Julien Cabe, Ingrid De Chazeron, et al.
Pageof 2